Refractory thrombotic thrombocytopenic purpura associated with primary sjogren syndrome treated with rituximab: A case report

American Journal of Therapeutics

Volumn 21, Issue 2, 2014, Pages

  Toumeh, Anis ^a   Josh, Navpreet ^b   Narwal, Rawan ^b   Assaly, Ragheb ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^b ST VINCENT MERCY MEDICAL CENTER   (United States)

Author keywords

Refractory; Rituximab; Sjogren syndrome; Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

AUTOANTIBODY; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CARDIOMEGALY; CASE REPORT; CONGESTIVE HEART FAILURE; CRACKLE; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FOOT EDEMA; HEART EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIP BIOPSY; LUNG AUSCULTATION; MIDDLE AGED; PLASMAPHERESIS; PRIORITY JOURNAL; RETICULOCYTE; SJOEGREN SYNDROME; SYSTOLIC DYSFUNCTION; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84896403254     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182459aa0     Document Type: Article

References (31)

1. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol. 2003;14:1072.
2. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int. 1987;32:292.
3. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995;48:2.
4. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60:831.
5. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpurahemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60.
6. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004;41:60.
7. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223.
8. Caramaschi P, Riccetti MM, Pasini AF, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura. Report of three cases and review of literature. Lupus. 1998;7:37-41.
9. Steinberg AD, Green WT Jr, Talal N. Thrombotic thrombocytopenic purpura complicating Sjogren's syndrome. JAMA. 1971;215:757-761.
10. Agapitos E, Pavlopoulos PM, Viapoulos G, et al. Primary Sjogren's syndrome complicated by hemolytic uremic syndrome. Scand J Rheumatol. 1996;25:263-265.
11. Settefrati N, Bonomini M, Lodi M, et al. Sjogren's syndrome associated with hemolytic uremic syndrome as the presenting clinical manifestation. Nephrol Dial Transplant. 1996;11:2316-2319.
12. Campbell GN, Gallo JH. Relapsing thrombotic thrombocytopenic purpura (TTP) in Sjogren's syndrome. Aust N Z J Med. 1998;28:214.
13. Schattner A, Friedman J, Kelpfish A, et al. Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren's syndrome. Clin Rheumatol. 2002;21:57-59.
14. Levy GG, Motto DG, Ginsburg G. ADAMTS 13 turns 3. Blood. 2005;106:11-17.
15. Pagano L, Marra R, Paoletti S, et al. Factor VIII complex in progressive systemic sclerosis. Clin Exp Rheumatol. 1986;4:319-321.
16. Woolf AD, Wakerley G, Wallington TB, et al. Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis. 1987;46:441-447.
17. Moake JL, Rudy CK, Troll JH, et al. von Willibrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura. Am J Med Sci. 1986;291:47-50.
18. Makoto N, Masanobu K, Fumihiro T, et al. Thrombotic thrombocytopenic purpura as a complicating factor in a case of polymyositis and Sjogren's syndrome. Am J Clin Pathol. 1990;94: 217-221.
19. Bianchi V, Robles R, Alberio L, et al. von Willibrand factor-cleaving protease (ADAMTS 13) in thrombocytopenic disorder: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100: 710-713.
20. Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043.
21. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106:1262.
22. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103:4514.
23. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine. 2004;83:233.
24. Amorosi EL, Ultmann JE. Thrombotic Thrombocytopenic purpura: report of 16 cases and review of literature. Medicine. 1996;45:139-159.
25. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura: Canadian Aphresis Study group. N Engl J Med. 1991; 325:393-397.
26. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932.
27. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451.
28. George JN. Controlling chronic TTP (editorial). Blood. 2005;106:1896.
29. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28:385.
30. Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher. 2008;23:151.
31. Franchini M, Veneri D, Lippi G, et al. The efficacy of Rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost. 2006;96: 119-125.